PARSIPPANY, N.J.--(BUSINESS WIRE)--April 4, 2006--The Medicines Company (NASDAQ: MDCO - News) today announced that the first patients have been enrolled in pivotal Phase III clinical trials evaluating cangrelor, a fast-acting, reversible, intravenous (IV) antiplatelet agent for preventing platelet activation and aggregation during the clotting process. If the trials are successfully completed and cangrelor receives regulatory clearance, the Company believes cangrelor will be the first IV platelet inhibitor to market that binds directly to the P2Y12 receptor, a clinically validated target to treat or prevent arterial thrombosis in patients undergoing percutaneous coronary intervention (PCI).
